GLP-1 (Byetta, Januvia, Janumet, Victoza Onglyza)

On March 14, 2013, the Food and Drug Administration announced new evidence indicating that Januvia can cause “precancerous cellular changes” in the pancreas. Researchers at the University of California Los Angeles determined the drugs increase the mass of the pancreas. Also, according to a study published in Gastroenterology, people who take these drugs to help manage diabetes are 2.7 times more likely to develop pancreatic cancer.